Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
particle FOLLOWSJohnson & Johnson’s leadand report the expected financial hit fromTARIFFimposed by Trump administration.
On a call of April 24 executives say they expect $ 200 million in tariff-related costs from $ 8.83- $ 9.97 per share.
The news comes in a week after J & J Executive says they expect $ 400 million in costs that end at the tariff of 2025.
Robert Davis, Merck’s Chairman and CEO, said during the income that the effect would come from existing tariffs implemented “between US and China, and Canada and Mexico.”
Although theTHREATSIn Pharmaceutical Tariffs who follow the Department of Commerce announcement on the Trump of the National Security Information on Pharmaceutical Implations in Pharmaceutical Implations with Pharmaceutical Implations in Pharmaceutical Implations Pharmaceutical imports to pharmaceutical imports to pharmaceutical imports in pharmaceutical imports in pharmaceutical imports, Davis has no worries.
“With regard to the potential additional US tariffs specific to pharmacists, our global supply chain and current inventory levels put potential effects,” he said.
When asked during earnings calls how Merck prepares for potential Pharmacutical Tarka, Davis introduces priorities, and revisiting the external manufacturing, and building internal manufacturing.
Merck invested $ 12 billion to make US officials since 2018 and plans to invest an additional $ 9 company investments for US employment as well as US opportunities
Zooming out.Merck is not the only ones highlighting US investments.
The J & J Executives in March says the company plans to invest $ 55 billion in US production in the next four years. And in February, Eli Lilly Executives say that the company invests at least $ 27 billion to open four new US-based plants over the next five years.
All three drugmakers say their decisions to expand the production of the US because of 2018 cut in 2018, which lowers taxable companies for pharmaceutical companies.
Tax Policy, Rather Than Tariffs, is a “very effective tool to be able to build manufacturing capacity here in the US, both for medtech and pharmaceuticals,” J & J CEO Joaquin Duato said during the company’s earnings call.
A quick rundown.Selling around the world in Merck for Q1 2025 about $ 15.5 billion, under 2% from Q1 2024.
Despite the humiliation of 2025 expected by the profit, the company says it still looks forward to the world of sale in full $ 64.6 billion this year.
Merck also prepares for blockbuster cancer drug keytrudada, which is lonely recounts for more than $ 7,29. Expected to expect Leerkink Partners.
This report is Originally published by Health Care.
This story originally shown Fortune.com
